These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2882050)

  • 1. Anti-ulcer drugs in antisecretory doses for "cytoprotection" in arthritic patients?
    Londong W
    Klin Wochenschr; 1986; 64 Suppl 7():32-4. PubMed ID: 2882050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic efficacy of misoprostol in peptic ulcer disease.
    Watkinson G; Hopkins A; Akbar FA
    Postgrad Med J; 1988; 64 Suppl 1():60-77. PubMed ID: 3138682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSAID-induced gastrointestinal damage. A critical review of prophylaxis and therapy.
    McCarthy DM
    J Clin Gastroenterol; 1990; 12 Suppl 2():S13-20. PubMed ID: 1978842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
    Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs: an update.
    Dajani EZ; Agrawal NM
    J Physiol Pharmacol; 1995 Mar; 46(1):3-16. PubMed ID: 7599335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds.
    Scarpignato C; Pelosini I
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of nonsteroidal anti-inflammatory drug-induced gastropathy.
    Scheiman JM
    Am J Manag Care; 2001 Feb; 7(1 Suppl):S10-4. PubMed ID: 11225347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
    Thomson AB; Mahachai V
    Clin Invest Med; 1987 May; 10(3):152-70. PubMed ID: 2887321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy.
    Yeomans ND
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S89-92. PubMed ID: 10379475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
    McCarthy DM
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of misoprostol to ranitidine in non-responders to H2-blockers and pirenzepine.
    Walker S; Sarem-Aslani A; Treiber G; Klotz U; Bode JC
    Neth J Med; 1991 Feb; 38(1-2):18-23. PubMed ID: 1674363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in clinical therapeutics: peptic ulcer disease.
    Siepler JK; Mahakian K; Trudeau WT
    Clin Pharm; 1986 Feb; 5(2):128-42. PubMed ID: 2869852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoprotection of gastroduodenal mucous membrane with analogues of prostaglandins.
    Lauritsen K; Laursen LS; Rask-Madsen J
    Recenti Prog Med; 1989 Jun; 80(6):344-52. PubMed ID: 2672199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract.
    Hirschowitz BI
    Gastroenterologist; 1994 Sep; 2(3):207-23. PubMed ID: 7987619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy and prevention of peptic lesions by prostaglandins].
    Müller P; Dammann HG; Simon B
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():166-74. PubMed ID: 3116777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials.
    Rostom A; Wells G; Tugwell P; Welch V; Dubé C; McGowan J
    J Rheumatol; 2000 Sep; 27(9):2203-14. PubMed ID: 10990235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and prevention of nonsteroidal anti-inflammatory drug induced gastrointestinal mucosal injury.
    Agrawal NM; Dajani EZ
    Int J Clin Pharmacol Res; 1989; 9(6):347-57. PubMed ID: 2576801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of NSAID induced gastroduodenal ulcers].
    Hansen JM; Bytzer P
    Ugeskr Laeger; 2001 Oct; 163(44):6103-5. PubMed ID: 11715151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of prostaglandin derivatives and mucoprotective drugs in treatment and prevention for NSAIDs-induced ulcer].
    Fujikawa Y; Watanabe T; Tominaga K; Fujiwara Y; Sato H; Arakawa T
    Nihon Rinsho; 2011 Jun; 69(6):1039-43. PubMed ID: 21688624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.